Ansa Biotechnologies, Inc., a prominent name in DNA synthesis, has announced the successful closure of $45.2 million in funding, along with commitments for an additional $9.2 million, as part of an oversubscribed Series B financing round. The round was spearheaded by Cerberus Ventures, with participation from Blue Water Life Science Advisors, Altitude Life Science Ventures, and other existing investors. New investors included Fall Line Capital, AIM13, and Black Opal Ventures. "We believe Ansa’s guaranteed approach fills a huge unmet need, and should become the new standard for DNA synthesis,” said Chenny Zhang, Director at Cerberus Ventures. With this financing, Chenny Zhang and Yanniv Dorone, PhD, Senior Vice President at Fall Line Capital, will join Ansa’s board of directors, bringing their extensive technical expertise and diverse industry experience to support Ansa's long-term strategic objectives. The funds will allow Ansa to broaden its manufacturing capacity in the U.S., enhance customer experience, and continue fostering strategic partnerships and technological advancements. These initiatives aim to introduce innovative applications that help customers accelerate their scientific endeavors and support the industry's transition from reading genomes to writing them. “Ansa is leading a fundamental shift in DNA synthesis,” remarked Zhang. “For decades, the market has been limited by an unreliable and outdated process. Ansa’s management team has done an excellent job demonstrating that scientists can finally get what they need, when they need it. We believe Ansa’s guaranteed approach fills a huge unmet need, and should become the new standard for DNA synthesis.” In the transition from the DNA reading era to the DNA writing era, traditional chemical DNA synthesis has shown significant limitations, particularly in synthesizing complex sequences. Ansa is set to redefine these possibilities with a proprietary enzymatic platform that offers both the length and complexity necessary for designing and assembling essential DNA constructs at scale. This sustainable approach avoids harsh chemicals, thereby preserving DNA integrity and enabling the synthesis of longer, more intricate sequences. This innovation unlocks previously unreachable areas of the genome, allowing scientists to engineer new pathways and accelerate breakthroughs in gene and cell therapy, vaccines, agrigenomics, and synthetic biology. For years, DNA synthesis has been restricted to short, simple constructs, preventing scientists from designing at scale and achieving the necessary precision for the next biological era. Ansa is now capable of delivering clonal DNA up to 50 kilobases in industry-leading times. By overcoming the challenges of length and complexity, Ansa equips researchers with the tools to design and assemble large DNA sequences that traditional providers struggle to produce reliably. The demand for Ansa’s services has surged since its commercialization began, leading to the introduction of the Ansa On-Time Guarantee, which ensures customers that their orders will be shipped in full and on time, or they pay nothing. Additionally, a new pricing model for low-complexity DNA sequences has been implemented, ensuring access to premium DNA without sacrificing complexity or turnaround time. “Our first year of commercialization proved what we already believed: reliability wins,” stated Jason T. Gammack, Chief Executive Officer of Ansa Biotechnologies. “When you can deliver 50 kb of clonal DNA in 24 days or less, when you’re the only company bold enough to guarantee entire orders, and when you keep innovating on behalf of customers instead of protecting the status quo, you don’t just compete, you reset the rules. This financing is fuel for the next phase of our mission: to make DNA something scientists can count on, every single time.” Entirely manufactured in the United States, Ansa’s DNA products are designed for seamless integration into existing workflows, empowering the next generation of biological discovery. For more information about Ansa’s offerings, please visit www.ansabio.com/products. About Ansa Biotechnologies Ansa Biotechnologies is at the forefront of redefining DNA synthesis with a commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is straightforward: complete orders on time or it's free. This unprecedented service reliability is enabled by Ansa’s expert team and proprietary enzymatic synthesis platform, which can produce highly complex DNA elements that traditional methods struggle to achieve. Ansa delivers sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. Headquartered in Emeryville, Calif., Ansa is empowering a global community of scientists to drive breakthroughs in healthcare, life sciences, and other industries reliant on synthetic DNA. For more details, visit ansabio.com or follow the company on X, Bluesky, and LinkedIn.